Recommendations for the use of next-generation sequencing (NGS) for patients with advanced cancer in 2024: a report from the ESMO Precision Medicine Working Group
M.F. Mosele(Inserm), Fabrice André(Inserm), Aldo Scarpa(University of Verona), C. Serrano(Vall d'Hebron Hospital Universitari), Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Ivan Bièche(Centre National de la Recherche Scientifique), E. Rouleau(Institut Gustave Roussy), A Stenzinger(Heidelberg University), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Anna M. Czarnecka(The Maria Sklodowska-Curie National Research Institute of Oncology), C. Benedikt Westphalen(LMU Klinikum), Nicola Normanno(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Jordi Remón(Vall d'Hebron Hospital Universitari), Stefan Michiels(Institut Gustave Roussy), Rowan Miller(Queen Mary University of London), R. Dienstmann(Universitat de Vic - Universitat Central de Catalunya), Ariane Bayle(Inserm), Funda Meric‐Bernstam(The University of Texas MD Anderson Cancer Center), Jorge S. Reis‐Filho(AstraZeneca (France)), Elena Castro(Research Institute Hospital 12 de Octubre), Jean-François Bonastre(Inserm), Fabrice Barlési(Hôpital Nord), A. Krämer(German Cancer Research Center)
Cited by 343
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
AACR Project GENIE: Powering Precision Medicine through an International Consortium
|Cancer Discovery|2017|2k